
Loading summary
A
So I think there's a very interesting and quite terrifying biodefense problem that I've been thinking a little bit about with some of our companies recently, which is if cyber was like the recent iteration of like the kind of quote unquote, fashionable way of attacking adversaries and maybe more traditionally that was actual physical weapons, I think the next iteration of that is probably using bioweapons. And I think that the way that plays out is using AI. I think AI's ability to create new protein structures that can evade traditional vaccine. Really powerful and a little bit scary. There's a very, very linear correlation between reporting cadence and performance of a company. As companies tend to go downhill, reporting tends to get sloppier. It isn't as extensive, it isn't as frequent. We can generally tell we've seen enough companies now to tell from those signals.
B
You mentioned founder breakups. It's arguably the number one issue for seed stage startups that fail. How does a company go about navigating a founder breakup? You decided to drop out at the age of 20 from Oxford after getting accepted into Peter Thiel's fellowship. Tell me about that decision.
A
Yeah, my family didn't have like a history of going to Oxford every, every generation. And so it was a pretty kind of meaningful decision for me. But. But at the same time it was a supernatural decision, not least because the Teal Fellowship has obviously got an incredible reputation. But I think kind of more importantly, you know, I was at the right time for that decision. And it's definitely been among the most impactful decisions, if not top two or three most impactful decisions of to do.
B
There's only been a couple hundred Thiel Fellows and already some incredible breakouts like Ethereum, Oyo Room Scale, AI Polkadot, to name a few. What do you attribute to the success of the Thiel Fellowship? Why. Why is there such a high hit rate?
A
It's a maybe a mindset or mentality of the kind of person who has not only taken the initiative to build a company during college, but also and to do so, you know, with some traction or some kind of early success. But two, to kind of have the, I guess the internal drive to drop out and pursue this full time against all of the social pressures and all of the social norms. I think that takes a certain kind of attribute in terms of personality. And I think that combined with frankly the Teal foundation and Teal Fellowship's ability to find those people and bring them together, I think that combination is pretty unique. And I think the fact that it hasn't scaled in some ways is the feature, it's by design and I think it very much contributes to such a high hit rate of success. I think that the, you know, the kind of more formulaic programs that are more scaled ultimately will have a higher number of unicorns on a number basis or a higher number of successful outcomes on a number basis. But the percentage hit rate likely won't be as high even though you have more shots on goal.
B
I think there's a couple of factors there. One is the Teal Fellows are figuratively burning the boats. They're dropping out of college in order to pursue something. So they're all in, in that kind of focus. I think the second one is obviously, you know, it's, it's picked from tens of thousands of applicants and you know, these are like the elite, the most, most elite, the highest IQ people. And then of course I think the Thiel Fellowship itself has become a sort of signal or a self fulfilling prophecy. Once you're in the Thiel Fellowship, you're able to raise a lot of capital and then that obviously significantly increases the chances of success. Success.
A
Yeah, I definitely think there is some self fulfilling kind of attributes to it. The same as you have with any kind of like elite community or some sort of, you know, high profile kind of, you know, community or in many other cases awards and things like that. I definitely think that contributes to it. And I think as the fellowship evolves, the concept of dropping out of university to start a company is still rare, but not as rare. But I think that, that you'll see a complete kind of refocus on big ideas, which I think is critically important.
B
You mentioned portfolio construction. You have strong views on portfolio construction for seed stage. What are your views on how portfolios should be constructed?
A
I guess why we've chosen to think about things the way we have at tbc. Our view is that with a slightly larger team than your average seed fund at eight people, we have an ability to you work with founders in a more proactive way than maybe you could do if you were two people. And so that enables us to build strong relationships with our founders in an operating capacity that really gives us a few different advantages, but hopefully adds commensurate value back to the founders in what they're able to extract from that in terms of the kind of two way trade or the two way dialogue. And so for us, our advantage in doing that is, is something that leads to our ability to have a more concentrated portfolio construction, which is our kind of information Asymmetry, it's how can you make a kind of comprehensive decision in the rosiest picture of what a founder's story is going to be, which is your first investment decision? The first time you ever meet a founder, regardless of the context of the situation, it will ultimately be the most packaged and best picture of the business, which is ultimately the job of a good founder. And so your first investment decision probably will, it may be your best, but it statistically is likely to be your worst. From like a data to kind of information perspective. And so you know, the, the ability to leverage a larger team, to have an extended diligence process post investment and then double down on winners is something we feel very, very strongly about. And so our construction is relatively concentrated to seed stage. We do about 30 companies every fund cycle. The ownership at entry, which, which we can also talk about in a second for us is percent at entry, which is slightly lower than your conventional 20% of your leading grounds that you'd see in most funds.
B
You mentioned that you have an informational advantage as an existing investor. Tell me about that informational advantage.
A
Yeah, I think this really comes down to your approach post investment for portfolio success. So I think you kind of really have three schools of thought there again or three strategies there. Some highly diversified seed firms who have limited resources but they want to get a large base of companies, they probably aren't spending huge amounts of time working with their companies day in, day out. There's just a resource constraint and being able to do so. And so I think that limits your ability to have information and thereby likely means that you should be spending the bulk of your dollars in your initial investment and trying to optimize for the lowest possible price. I think that's kind of got to be the strategy there. I think the other end of that is a kind of a multi stage firm who is using seed stage as a kind of an option on supporting companies whether they take a board seat or is kind of bifurcating there. But let's say they do take a board seat. The relationship tends to be relatively governance heavy. It's like I come to my board meeting, I'd like to understand what's going on and I'd like to help you make a couple of key decisions. And that's quite high level and quite specific to some very, very key decisions. If they choose not to take a board seat, they probably have that same lack of informational advantage because they're really ultimately waiting for a large round and using their initial investment to kind of get them in the door. And then I think you have kind of a strategy in the middle which is if you can come up with a mechanism to have more resources, you can have a slightly more concentrated portfolio, but you can spend significantly more time with those companies outside of board meetings. And I really emphasize outside of board meetings because I think board meetings are kind of the default place where VCs interact with companies and founders. But I think they are probably the worst place to get into the real kind of bones of what's going on at a company.
B
So essentially it's really a two way street. Your informational advantage comes from being involved with a company and helping and the company gets that as a value from you as an investor.
A
Correct? That's exactly how I view it. It has to be a two way street. It has to be organic. You know, the information requests aren't something that a founder wants. I've been on that side of the table. Every time I get asked for information, it distracts from me doing my core job. But if I'm being asked for information as a mechanism for me to be able to, let's say, receive an introduction or something that is relevant and something that furthers my goals, that kind of two way street means that I'm very, very willing to play ball and give that information because it's value added to me to have that engaged relationship.
B
To play devil's advocate, how do you scale this value added strategy?
A
That's a super valid question. I think it ultimately doesn't scale infinitely. For example, if you continue to put the same amount of effort into every company on a kind of evenly distributed basis, that becomes very challenging. We as a firm twice a year get together and we actually have all of our team blindly stack rank our portfolio companies on a series of different metrics that give us a sense of the time input to progress of the company and how they continuously are performing. If a company is stopping reporting, is being less communicative, is ultimately growing slower, and we don't think we're going to allocate significant follow on dollars to that company. We do make a conscious decision to red the cadence and volume of people on our team that are working with that company. That's not to say that we abandoned them or don't pick up the phone. But ultimately we are in the business of trying to work out which companies are going to succeed and allocating our resources accordingly. And thereby we have to be conscious despite having an eight person team as to how we do that.
B
The dirty secret of VC is that every VC has their favorites and they're less favorites and don't always spend an equal amount with every startup.
A
That's ultimately the business model that venture capital firms have to upfront about. It is a game where some companies will ultimately return the vast majority of the capital and others will not. And I think as long as that's kind of front and center, I think the expectation needs to be. If you're, if your company is struggling and you need our help, we will be there. But ultimately our proactivity is obviously going to go towards the companies that are progressing the best and the fastest and who are ultimately on that kind of two way journey with us, who are playing, you know, the, the, the game that we are playing in terms of we need the communication, we need the consistency of reporting, et cetera to be able to do that. And I think there's a very, very linear correlation between reporting cadence and performance of a company. As companies tend to go downhill, reporting tends to get sloppier. It isn't as extensive, it isn't as frequent. We can generally tell we've seen enough companies now to tell from those segments.
B
When we were last chatting, you mentioned that you tell every founder, text me with good news, text me with bad news. How do you get founders to open up and text you with bad news?
A
It's really nuanced, right? And you can't expect to see everything in real time. But I do really believe that the quality of your relationship with the founder and explicitly that not being in a board setting I think is really important. Like we really do invest the time to try and build that relationship. We do work with founders to set those micro goals that aren't the macro goal of the company. But what are the specific things you're trying to achieve in working back from your next financing round or for your next milestone. And I think by being integrated into that flow, I think it's easier to see those things. Of course we get blindsided the same way as other people get blindsided. It's not to say that we see everything, but I think even if we see 50% more, that's a significant difference for us in our ability to plan how to one, allocate resources and to support those companies in advance. I think making it clear early on that we can only help you if we find out before it's too late. For example, if you're having a really big problem with your co founder and you would like to part ways with your co founder, knowing that before you're getting into a legal dispute, or before you're trying to figure, you know, figure out how to transition them out is critically important. We can only help you if we know that in advance. I think it's just things like that, encouraging that behavior early on and being hugely transparent as well. One thing I think VCs do quite badly in general with managing expectations and things like follow on, things like decision to do pro rata, all of those types of decisions. By being super, super candid and transparent early on as to how we make decisions, why we generally don't do bridges, even if they seem like a great deal, unless our information tells us that it is a great deal, things like that. We don't do things just for signaling, which I think a lot of people do. And I think being really transparent around that whole process and how we think about those things and our philosophy is really important.
B
You mentioned founder breakups. It's arguably the number one issue for seed stage startups that fail. How does a company go about navigating a founder breakup? Thank you for listening to join our community and to make sure you do not miss any future episodes, please click the Follow button above to subscribe.
A
It's a really challenging and nuanced situation in every case by case. So I think it's hard to generalize. But what I would say is getting to the kind of core of the motivations on both sides and cutting through those emotions to what is the most productive thing for the vision of the company. Is it a vision dispersance? Right. So is it. I. I think the company should go in this direction. You believe the company should go in this direction. That's a very different situation to we just can't get on and communicate anymore. That's a communication breakdown. Or, you know, a secondary. You know, should we be taking a secondary? Should we. There's all kinds of nuances to that. I think it's getting to the nub of what is the problem? Is it we're in the wrong role? That often happens. The CEO and the cto there's a friction or in chief scientific officer and there's some friction around who's in that role. And there's obviously always some egos at play. You have to have a certain amount of ego to be a founder. And so I think it's really getting to the core of that and then working backwards from that. How do we solve that? Is it a complete breakup? Is it a moving role? Is it a change in equity or compensation that there's always some way to solve it? And I think not moving to lawyers immediately and not moving to kind of a toxic situation immediately is really important and I think having a mediator who is somewhat unbiased is really important for that.
B
There's a lot of funds in the market. How would you explain to the LP or allocator community TVC source of alpha?
A
It's a combination of a few different things. I think it's hard to kind of point to just one thing. I would say the first thing I think very importantly is where we choose to focus. I think there is an under emphasis on thesis driven investing in venture. I think over the years venture has become relatively concentrated into a few different categories. So white collar enterprise and B2B software, consumer Internet. We've very proactively decided to be quite thematic and thesis oriented in how we choose to invest. And I think that is a source of alpha in itself. I think staying close to what the roots of venture capital actually are, that is investing in ambitious people building very innovative things. I think that's really important and I know that sounds quite trivial, but I do think we've kind of gotten into a cycle of an ability to make money by by using existing technological progress and applying spend on marketing dollars or things like that to generate returns. And I don't know if that necessarily is kind of the core of venture capital or what will sustain. And so for us that is spending a lot of time forming points of view and working out where the right communities of both investors and founders are within categories that we think are interesting. So for us, we think we're at a very, very interesting pivotal moment in the health care system right now around personalization data and the applications of AI and computational biology in reducing the risk of operating in the health care industry whilst increasing the return profile because you are driving better outcomes at lower costs for people. So I think that's really important. And then we secondarily, thematically believe you on that, on that point that the physical world around us is going to go through a bit more of kind of an industrial transformation or some sort of re industrialized process where everything will both become more sustainable. So I think there's a very important moment in time where things need to be efficient, cheap, low cost, at the same time as being more sustainable, which we firmly believe that there is an opportunity in with computational biology and chemistry and AI.
B
You mentioned a couple of categories that could be categorized as deep tech and obviously there's a lot of opportunity there, but a lot of it takes a lot of capital. How do you make sure that your Portfolio math makes makes sense in order to invest in these deep tech startups.
A
The capital intensity and also the time duration are probably the two biggest kind of risk factors or criticisms that people make in investing in deep tech. And I certainly think that has been the case historically. I would say we can simulate a lot of things, especially things that are not too hardware heavy in advance. So I think there is a huge advantage right now in the kind of intersection of computational power or applied AI with biology and chemistry, specifically in those kind of physical world aspects of deep tech and also to a certain extent within the health care system on the bio side as well. So I think that there is a multi year trial and error R and D process in some ways that can get avoided through these abilities to simulate things at scale. And I think that that will only get better and easier. And I do think that's like three to five years of the journ. Quite a lot of expense and risk can be automated pretty significantly. And you see that now also in the ability to simulate things that are capex heavy, which also take a lot of trial and error, which I think is really important. So I think that's the first thing. I think you can compress those cycles significantly. And the second thing is the outcomes can just be bigger. I think people always underwrite to the unicorn valuation like the billion dollar kind of magic number. I think you will start to see many deca unicorns beyond using deep tech or kind of more kind of transformative IP rich things where they are kind of either winner takes all markets or oligopolies that can be close to kind of winner takes all markets where you will see just transformatively big outcomes. You've obviously already seen it in your SpaceXs, Openais, Xais, et cetera of the world. And there will be a long tail of a lot more of those companies over the coming years. So I think you can make the math work by just underwriting to a bigger outcome. But I also think that the dilution historically was heavy because less investors invested in those categories. I think as more and more investors start to invest in American dynamism and a lot of these things that intertwine with deep tech generally just by nature of what they are, you will see see that capital come in and thereby you will see less dilution.
B
Seen a lot of excitement around defense tech. Do you think the time has come for defense tech to really make venture like returns for investors?
A
There is an enormous amount of government funding still maybe in the last administration went pretty heavily to like climate Tech and things like that. I think you'll see a lot of that go into kind of the American dynamism on shoring of critical things to the us. Some of that is defense, some of that is is. Is more kind of independence or self sovereignty. But I think that you will see a huge amount more investment there subsidized and supported by government funding. Absol. But I see a lot of investors who were very anti investing in defense a few years ago, to a certain extent anti investing in deep tech generally now shifting their focus a little bit because it's become both more acceptable but also more subsidized and also more in the kind of forefront of people's perspectives and minds. And obviously this incoming administration is all about self sovereignty of the US and bringing things back to being produced here. And so I think that that is going to have to come with a level of subsidization. Labor is just more expensive here. But I think the applic of AI and robotics will reduce that cost significantly and so will I think kind of start to equitize that a little bit.
B
I think you've seen a similar shift in sentiment on the LP side. If you're an LP side. If you're an L.P. today and you're trying to invest in venture in the large funds, you really can't avoid defense tech. So I think some of those policies have been changing really in real time. When when we last spoke you mentioned that most VCs are momentum investors, but TVC is not a momentum investor. Unpack that for me.
A
Comes down to your ability to pick areas not based on what is hot right now, but what could be hot in future. I think that it's trivial in what it sounds like, but in reality it takes a lot of work forming points of view and not looking at what the market is doing and informing those points of views with a fundamental first principles approach is really kind of counterintuitive to what we've seen over the last 10 or 15 years in venture where I think the real innovation happened for the last kind of decade or so of the Internet era. A lot of that real innovation happened in the prior decade with the cloud or the new cloud and the App Store and the move to mobile. A lot of those things enabled significant convenience improvement for your average person's life, which generated a huge amount of momentum behind things that could capture parts of that value stack. I think the interesting thing about that is if you look at the most fundamental industries in the US and further afield, things like the production of what we eat or the things that drive the manufacturing of all of the goods that we consume, like a lot of these physical world things and to a certain extent healthcare. But more specifically these physical world areas, a website or mobile app may be improved people's businesses a few percent or maybe even 10%, but they didn't improve them hundreds of percent like you saw in the kind of more of the white collar service industries. Right. So for someone, you know, who was a farmer in a field, you know, the web era didn't really impact them. Whereas the computational biology era or the applied AI and robotics era, where their jobs are getting, you know, much more high margin and they are able to kind of elevate themselves and use robots for the lower margin things or use new products to, to ensure that crops are protected or other things like that, that is a huge multi hundred percent improvement on the efficiency of running their business. And that I think drives real innovation. I think we're about to see that in the same way as in white collar industries. We saw that with websites and mobile apps and software platforms, et cetera.
B
You mentioned computational biology. What are the opportunities that you see in computational biology today?
A
Both computational biology and chemistry are very interesting now that AI is getting so good at simulating. Let's take, let's take the kind of the health care system to begin with. We give someone a vaccination or we give someone a therapeutic by putting something that is foreign into the body and having it work its magic, quote, unquote. I think that's, that's, that's not the future of medicine. I think the future of medicine is getting the body to produce things it already does every day, but on demand, with the right payload or the right, you know, dosage. On demand. Right. So I think the, our ability to interface with our core critical intelligence, intelligent systems. The brain is not the only intelligent organ in the body. Our immune system and our ability to fight foreign things and read and write what's coming into the body is, is not equally as intelligent, but is extremely intelligent. And our ability to interface with that and then apply AI to personalize that, that is like an incredible move forwards and shift in our ability to do things. And it's a lot cheaper for the healthcare system. So that will be, I think, very transformative. That's kind of probably one example and then maybe more in the physical world a lot of the kind of commodit that we consume every day right now that aren't sustainable. Take surfactants for example. Surfactants are in every detergent cosmetics products, sunscreen, food, color and everything around us. It's not sustainable and it hasn't really been innovated on for a long time, but it's effectively in the most simplistic terms, kind of like the binding agent that redoing things like that with new methodologies computationally and ensuring that it is both low cost and cheaper, but also sustainable. That kind of stuff we're going to see kind of day in, day out, not with a green premium, but at like cost parity or lower than cost. And redoing the physical world around us with that overlay, I think is really, really interesting and will be hugely important for things like preventing wildfires and hurricanes and things that happen right now which are deadly and devastating for people.
B
To borrow Peter Thiel Question what do you believe about venture capital that very few others believe?
A
Gosh, that's a tough question, I think, whether very few others believe this, or maybe I'm packaging it slightly differently. I think very few people believe that the current state of venture capital is not really investing in innovation, but is instead investing in ideas that have already played out. I think the kind of contrarian perspective that I will hammer home forever is that that the rate of innovation is so rapid right now and everything that we see and do is so significant in terms of the rate of change right now that the things that we thought, things that maybe took 10 years to play out last cycle, I think are playing out in months and maybe years right now. And so if you don't take a very, very thesis driven approach to figuring out what is going on in the world and where the opportunities are, I think you get left behind. I think we're going to see see the biggest shift in venture capital that we've seen. Probably at least since I've been even thinking about the concept of venture capital, and probably even since I've been thinking about the concept of a company and building a company in entrepreneurship in the next few years, not because of a reallocation of capital by LPs and allocators, but based on just the relevance of the things that people are focusing on and how rapidly that will shift. That's my my big kind of bet and thesis.
B
What's an example of something that some people might think is going to be five, 10 years away that you think may develop in 2025?
A
So I think that's a very interesting and quite terrifying biodefense problem that I've been thinking a little bit about with some of our companies recently, which is I think if Cyber was like the recent iteration of like the kind of quote unquote, fashionable way of attacking adversaries and maybe more traditionally that was actual physical weapons. I think the next iteration of that is probably using bioweapons. And I think that the way that plays out is using AI. I think AI's ability to create new protein structures that can evade traditional vaccines is really powerful and a little bit scary. And I think that it will take a reframing of how we both build biodefense capabilities, but just generally how we build vaccines and therapeutics to this. Arming the body in a personalized way with what the body already does right now extremely effectively, that play out, I think will happen very fast. It's scary for the world, but I think enough smart people are starting to think about that that I think that some of the smartest minds in the world who may be currently working on medicine may be working on biodefence pretty soon. And I think that's a pretty exciting thing if you're ahead of the curve and a terrifying thing if you ignore it. That is coming down the pipe right now.
B
What would you like our audience to know about you, about TVC or anything else you'd like to share?
A
Anyone who's trying to solve a very, very big problem that's challenging to solve, that wants a thought partner in doing so, Absolutely should come and talk to us. We're not scared of big ideas. We're willing to take risk there. The whole point of venture is taking risk. And for me, I personally am very, very excited by things that are obvious, big things that are around us that people think are so established and incumbent that no one should dare tackle them. Tackling those problems with a new perspective as to why that should be changed and with an approach that is very first principle. That's always exciting to me and I'm always down to have that conversation to think about how that can be best be financed.
B
Nick, appreciate you jumping on. Look forward to sitting down soon.
A
Absolutely.
Podcast Summary: How I Invest with David Weisburd – Episode E131: Can VCs Make Money in Deep Tech? with Nick Shekerdemian
Introduction
In Episode E131 of "How I Invest with David Weisburd," host David Weisburd engages in a profound discussion with venture capital expert Nick Shekerdemian. The conversation delves into the intricacies of investing in deep tech, the challenges of founder breakups, portfolio construction strategies, and the evolving landscape of venture capital. This comprehensive summary captures the essence of their dialogue, highlighting key insights, notable quotes, and critical conclusions.
Timestamp: 00:00 – 00:51
Nick Shekerdemian initiates the conversation by addressing a pressing and "terrifying biodefense problem." He draws a parallel between the evolution of cyber attacks and the potential future use of bioweapons enhanced by artificial intelligence.
Nick Shekerdemian [00:00]: "AI's ability to create new protein structures that can evade traditional vaccines is really powerful and a little bit scary."
Shekerdemian emphasizes the linear correlation between a company's reporting cadence and its performance, suggesting that declining reporting frequency often signals deteriorating company health.
Timestamp: 00:51 – 05:55
The discussion shifts to the critical issue of founder breakups, identified as the primary reason for seed-stage startup failures. Weisburd probes Shekerdemian's personal experience with the Thiel Fellowship—a prestigious program that encourages entrepreneurs to drop out of academia to pursue their ventures.
Nick Shekerdemian [01:10]: "Dropping out at the age of 20 from Oxford after getting accepted into Peter Thiel's fellowship was one of the most impactful decisions I've made."
Shekerdemian attributes the success of the Thiel Fellowship to the mindset and personality traits of its Fellows—individuals who are proactive, driven, and willing to defy social norms to achieve their entrepreneurial goals. He highlights the program's selective nature and its intentional lack of scaling, which contributes to its high success rate.
Nick Shekerdemian [01:49]: "The combination of the Fellows' internal drive and the Fellowship's ability to bring them together is pretty unique."
Timestamp: 04:00 – 10:45
Shekerdemian elaborates on portfolio construction strategies for seed-stage investments. He explains that their team of eight people allows for proactive engagement with founders, fostering strong relationships and enabling a concentrated portfolio approach.
Nick Shekerdemian [04:09]: "Our ability to work with founders in a more proactive way gives us a couple of different advantages, adding commensurate value back to the founders."
He discusses the concept of information asymmetry—the advantage gained by deeply understanding a founder's vision beyond the initial investment decision. This approach contrasts with more diversified seed firms that may not invest as deeply due to resource constraints.
Nick Shekerdemian [06:02]: "If you can come up with a mechanism to have more resources, you can have a slightly more concentrated portfolio and spend significantly more time with those companies."
Weisburd and Shekerdemian also touch upon the unavoidable reality that not all startups can receive equal attention. They acknowledge that while some firms may appear to favor certain startups, this is a fundamental aspect of the venture capital model, where a few investments typically yield the majority of returns.
Timestamp: 10:45 – 14:17
A pivotal part of the conversation centers on fostering open communication between VCs and founders. Shekerdemian shares his philosophy of encouraging founders to share both good and bad news, emphasizing the importance of a two-way street in these relationships.
Nick Shekerdemian [10:54]: "By being integrated into that flow, it's easier to see those things... encouraging that behavior early on and being hugely transparent is really important."
He underscores the significance of setting clear expectations and being candid about investment decisions, such as follow-on funding and pro-rata rights. This transparency helps build trust and ensures that founders are aligned with the VC's approach.
Timestamp: 14:17 – 16:28
When addressing the sensitive topic of founder breakups, Shekerdemian advocates for a nuanced, case-by-case approach. He suggests focusing on the core motivations of each party involved and striving to resolve underlying issues without immediately resorting to legal measures.
Nick Shekerdemian [12:59]: "Getting to the core of the motivations on both sides and cutting through those emotions is really important."
He emphasizes the role of unbiased mediators and the importance of maintaining the company's vision to navigate these challenging situations effectively.
Timestamp: 14:24 – 20:02
Shekerdemian discusses how his firm, TBC, differentiates itself in the crowded venture capital landscape. He attributes their "source of alpha" to a few key factors:
Thesis-Driven Investing: Unlike many firms that follow market trends, TBC maintains a thematic and thesis-oriented investment approach.
Nick Shekerdemian [14:24]: "There is an under emphasis on thesis-driven investing in venture... staying close to the roots of venture capital by investing in ambitious people building very innovative things."
Focus on Deep Tech: TBC concentrates on sectors like computational biology, chemistry, and AI, which are transformative and offer substantial returns.
Nick Shekerdemian [16:42]: "There is a huge advantage right now in the intersection of computational power or applied AI with biology and chemistry."
Avoiding Momentum Investing: The firm resists investing based on current market momentum, instead prioritizing long-term, first-principles opportunities.
Nick Shekerdemian [20:24]: "TVC is not a momentum investor... It takes a lot of work forming points of view and not looking at what the market is doing."
Timestamp: 16:28 – 22:40
Shekerdemian elaborates on the nuances of investing in deep tech, acknowledging the high capital requirements and extended time horizons. He argues that advancements in AI and computational simulations are mitigating some traditional risks associated with deep tech investments by compressing development cycles and reducing costs.
Nick Shekerdemian [16:42]: "We can simulate a lot of things... compress those cycles significantly."
He highlights the potential for "deca unicorns"—companies valued at over $10 billion—especially in sectors where deep tech can create winner-takes-all markets. Shekerdemian believes that the increasing influx of capital into these areas will also help reduce dilution for investors.
Timestamp: 18:47 – 20:02
The conversation shifts to defense technology, with Shekerdemian noting a significant trend of increased government funding in this sector. He observes that recent policies favoring American dynamism and self-sovereignty are making defense tech more attractive and subsidized.
Nick Shekerdemian [18:55]: "You'll see a lot more investment subsidized and supported by government funding... applying AI and robotics will reduce labor costs significantly."
This shift not only legitimizes defense tech as a viable investment but also aligns with broader national priorities, making it a fertile ground for venture investments.
Timestamp: 20:02 – 24:54
Shekerdemian articulates a contrarian view on the current state of venture capital, asserting that many VCs are not truly investing in innovation but rather in ideas that have already matured.
Nick Shekerdemian [24:54]: "Very few people believe that the current state of venture capital is investing in ideas that have already played out... the rate of innovation is so rapid right now."
He forecasts a significant shift in venture capital, emphasizing the need for thesis-driven investing to keep pace with unprecedented innovation rates. Shekerdemian believes that firms that fail to adapt will be left behind as the venture landscape evolves rapidly.
Timestamp: 22:40 – 26:22
Delving deeper into computational biology, Shekerdemian outlines transformative opportunities fueled by AI. He envisions a future where medicine leverages the body's innate capabilities, personalized through AI, to produce therapeutics on demand—ushering in a new era of healthcare efficiency and effectiveness.
Nick Shekerdemian [22:46]: "The future of medicine is getting the body to produce things it already does every day, but on demand, with the right payload or dosage."
Additionally, Shekerdemian points to sustainable innovations in chemistry, such as developing cost-effective and environmentally friendly surfactants, which could revolutionize industries from detergents to cosmetics.
Timestamp: 24:50 – 28:36
In response to Peter Thiel's question about unique beliefs in venture capital, Shekerdemian reiterates his conviction that the industry must evolve beyond chasing existing trends. He advocates for a focus on groundbreaking innovation driven by first principles.
Nick Shekerdemian [24:54]: "The things that we thought might take 10 years to play out are happening in months right now."
Concluding the episode, Shekerdemian invites ambitious entrepreneurs tackling significant challenges to engage with TBC, emphasizing the firm's commitment to supporting big ideas through risk-taking and innovative financing.
Nick Shekerdemian [27:50]: "Anyone who's trying to solve a very, very big problem... absolutely should come and talk to us."
Conclusion
Episode E131 of "How I Invest with David Weisburd" offers an in-depth exploration of venture capital strategies in the realm of deep tech. Nick Shekerdemian's insights shed light on the importance of thesis-driven investing, the potential of AI and computational biology, and the evolving dynamics of founder relationships. For investors and entrepreneurs alike, this episode underscores the necessity of adaptability, transparency, and a forward-thinking approach in navigating the complex landscape of venture capital.